CAR-T cell therapy neurotoxic complications predicted by Simple blood test

Written By :  Isra Zaman
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-09-02 04:15 GMT   |   Update On 2022-09-02 04:15 GMT
According to a recent study from Washington University School of Medicine in St. Louis, a quick blood test could help doctors determine which patients are more likely to experience neurotoxic side effects in the days and weeks following CAR-T cell therapy.
Analyzing blood samples from patients before, during and after CAR-T cell therapy, the researchers found that levels of a protein called neurofilament light chain (NfL) are higher in patients who go on to develop neurotoxic complications. High levels of the protein are present even before therapy begins, and those levels remain elevated throughout treatment and up to a month afterward.
Advertisement
The research, published in the journal JAMA Oncology, could help doctors anticipate these life-threatening side effects and allow them to begin giving treatments that can reduce the neurotoxic effects early during a patient's treatment. It also opens the door to developing ways to prevent the side effects or reduce their risk before CAR-T cell therapy begins.
A general marker of damage to neurons, the NfL protein has been used to measure or monitor the severity of several neurologic diseases, including Alzheimer's disease and multiple sclerosis.
Ref:
Omar H. Butt et al,Assessment of Pretreatment and Posttreatment Evolution of Neurofilament Light Chain Levels in Patients Who Develop Immune Effector Cell–Associated Neurotoxicity Syndrome,JAMA Oncology, DOI: 10.1001/jamaoncol.2022.3738
Full View
Tags:    
Article Source : JAMA Oncology

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News